CN118994363A - 抗突变的kras的t细胞受体 - Google Patents

抗突变的kras的t细胞受体 Download PDF

Info

Publication number
CN118994363A
CN118994363A CN202411133523.3A CN202411133523A CN118994363A CN 118994363 A CN118994363 A CN 118994363A CN 202411133523 A CN202411133523 A CN 202411133523A CN 118994363 A CN118994363 A CN 118994363A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
tcr
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411133523.3A
Other languages
English (en)
Chinese (zh)
Inventor
王琼
余致亚
詹姆斯·C·阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN118994363A publication Critical patent/CN118994363A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
CN202411133523.3A 2014-11-26 2015-11-24 抗突变的kras的t细胞受体 Pending CN118994363A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462084654P 2014-11-26 2014-11-26
US62/084,654 2014-11-26
US201562171321P 2015-06-05 2015-06-05
US62/171,321 2015-06-05
CN201580070673.7A CN107223134B (zh) 2014-11-26 2015-11-24 抗突变的kras的t细胞受体
PCT/US2015/062269 WO2016085904A1 (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580070673.7A Division CN107223134B (zh) 2014-11-26 2015-11-24 抗突变的kras的t细胞受体

Publications (1)

Publication Number Publication Date
CN118994363A true CN118994363A (zh) 2024-11-22

Family

ID=54838442

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202411133523.3A Pending CN118994363A (zh) 2014-11-26 2015-11-24 抗突变的kras的t细胞受体
CN201580070673.7A Active CN107223134B (zh) 2014-11-26 2015-11-24 抗突变的kras的t细胞受体
CN202111263859.8A Active CN113956349B (zh) 2014-11-26 2015-11-24 抗突变的kras的t细胞受体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580070673.7A Active CN107223134B (zh) 2014-11-26 2015-11-24 抗突变的kras的t细胞受体
CN202111263859.8A Active CN113956349B (zh) 2014-11-26 2015-11-24 抗突变的kras的t细胞受体

Country Status (16)

Country Link
US (3) US11207394B2 (https=)
EP (3) EP3223850B1 (https=)
JP (2) JP6863893B2 (https=)
KR (1) KR102622784B1 (https=)
CN (3) CN118994363A (https=)
AU (3) AU2015353720B2 (https=)
ES (2) ES2965689T3 (https=)
HU (1) HUE065689T2 (https=)
IL (1) IL252258B (https=)
MX (1) MX384919B (https=)
PL (1) PL3223850T3 (https=)
PT (1) PT3223850T (https=)
SA (1) SA517381608B1 (https=)
SG (2) SG11201704155UA (https=)
SI (1) SI3223850T1 (https=)
WO (1) WO2016085904A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118994363A (zh) * 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体
ES2879287T3 (es) * 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
HRP20221183T1 (hr) * 2016-08-02 2022-12-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T-stanični receptori anti-kras-g12d
WO2018069871A2 (en) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
WO2018208553A1 (en) * 2017-05-12 2018-11-15 Augusta University Research Institute, Inc. Human alpha fetoprotein-specific t cell receptors and uses thereof
AU2018269370B2 (en) * 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
KR20250037592A (ko) * 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
SG11202002635RA (en) * 2017-09-29 2020-04-29 The United States Of America As Represented By The Secretary Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
CR20200287A (es) 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
CN110016074B (zh) * 2018-01-08 2021-03-30 中国科学院广州生物医药与健康研究院 Mage-a3人源化t细胞受体
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
JP2021533777A (ja) * 2018-08-16 2021-12-09 ビオンテック ユーエス インコーポレイテッド Ｔ細胞受容体構築物およびその使用
EP3914612A1 (en) 2019-01-22 2021-12-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
WO2020237368A1 (en) * 2019-05-27 2020-12-03 Provincial Health Services Authority Immunotherapy constructs targeting kras antigens
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
US12577278B2 (en) * 2019-06-07 2026-03-17 Emory University KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
US12486334B2 (en) 2019-07-12 2025-12-02 The Regents Of The University Of California Chemically controlled monoclonal antibody target engagement
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
KR20220098379A (ko) * 2019-11-15 2022-07-12 그릿스톤 바이오, 인코포레이티드 공유 네오항원을 표적으로 하는 항원-결합 단백질
CN115279784A (zh) * 2020-02-12 2022-11-01 美国卫生和人力服务部 针对含有g12d突变的ras的hla i类限制性t细胞受体
KR20220143875A (ko) * 2020-02-14 2022-10-25 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12v 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
WO2021242961A1 (en) * 2020-05-27 2021-12-02 Vanderbilt University Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
AU2021309958A1 (en) * 2020-07-16 2023-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted DRB T cell receptors against RAS with G12V mutation
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
AU2022238389A1 (en) * 2021-03-19 2023-10-05 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
CN116063511B (zh) * 2021-09-30 2023-10-03 北京可瑞生物科技有限公司 抗原结合蛋白及其应用
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
JP2025504883A (ja) 2022-01-21 2025-02-19 テ－クニフェ ゲーエムベーハー 決定可能な親和性で特定のペプチドを結合する抗原認識コンストラクト、およびｋｒａｓに抗原特異性を有するｔ細胞レセプター、ならびに、対応する核酸配列、ベクター、宿主細胞、医薬組成物、およびキット
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114591443A (zh) * 2022-03-07 2022-06-07 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于scTv的嵌合受体CSR及其应用
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用
EP4584298A1 (en) * 2022-09-08 2025-07-16 The Regents Of The University Of California Binding agent recognition of drug-peptide conjugates
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물
KR20250143879A (ko) * 2023-01-13 2025-10-02 코레진 바이오테크놀로지 컴퍼니 리미티드 항원 결합 단백질 및 그 용도
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
AU2024309123A1 (en) 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
WO2025056656A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C
WO2025189363A1 (zh) * 2024-03-12 2025-09-18 广州医科大学 一种t细胞受体(tcr)及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
CA2651174A1 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
WO2008089053A2 (en) * 2007-01-12 2008-07-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
EP2478120B1 (en) * 2009-09-17 2015-09-02 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN104131034B (zh) * 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
CN118994363A (zh) * 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体
CN105802909B (zh) * 2014-12-31 2021-01-01 中国医学科学院基础医学研究所 具有her2特异性tcr的t细胞制备物及其用途
CN108395479B (zh) 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用

Also Published As

Publication number Publication date
EP4286407B1 (en) 2026-03-18
NZ732045A (en) 2024-04-26
CN107223134A (zh) 2017-09-29
AU2023200614A1 (en) 2023-03-09
SG11201704155UA (en) 2017-06-29
CN113956349A (zh) 2022-01-21
SG10201913978RA (en) 2020-03-30
IL252258B (en) 2021-12-01
JP2017536825A (ja) 2017-12-14
CN113956349B (zh) 2024-09-06
CN107223134B (zh) 2021-11-16
AU2015353720A1 (en) 2017-06-08
MX384919B (es) 2025-03-14
AU2015353720B2 (en) 2020-02-27
KR20170099905A (ko) 2017-09-01
EP3223850A1 (en) 2017-10-04
HK1243642A1 (en) 2018-07-20
JP7297807B2 (ja) 2023-06-26
US20170304421A1 (en) 2017-10-26
SA517381608B1 (ar) 2021-03-11
US20250263462A1 (en) 2025-08-21
US20220088164A1 (en) 2022-03-24
EP4286407A3 (en) 2024-03-06
JP6863893B2 (ja) 2021-04-21
WO2016085904A1 (en) 2016-06-02
ES2965689T3 (es) 2024-04-16
US11207394B2 (en) 2021-12-28
HUE065689T2 (hu) 2024-06-28
EP3666288B1 (en) 2023-09-27
SI3223850T1 (sl) 2020-09-30
EP4286407A2 (en) 2023-12-06
PL3223850T3 (pl) 2020-08-24
AU2020203465B2 (en) 2022-11-17
EP3223850B1 (en) 2020-01-08
EP3666288A1 (en) 2020-06-17
US12312391B2 (en) 2025-05-27
IL252258A0 (en) 2017-07-31
JP2021104044A (ja) 2021-07-26
KR102622784B1 (ko) 2024-01-09
MX2017006865A (es) 2018-01-11
CA2968399A1 (en) 2016-06-02
ES2784261T3 (es) 2020-09-23
PT3223850T (pt) 2020-04-13
AU2020203465A1 (en) 2020-06-18
AU2023200614B2 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
US12312391B2 (en) Anti-mutated KRAS T cell receptors
US12187779B2 (en) Anti-human papillomavirus 16 E6 T cell receptors
WO2016077525A2 (en) Anti-human thyroglobulin t cell receptors
HK40065450A (en) Anti-mutated kras t cell receptors
HK40031837A (en) Anti-mutated kras t cell receptors
CA2968399C (en) Anti-mutated kras t cell receptors
HK40065450B (zh) 抗突变的kras的t细胞受体
HK40031837B (en) Anti-mutated kras t cell receptors
HK40018191A (en) Anti-human papillomavirus 16 e6 t cell receptors
HK1243642B (en) Anti-mutated kras t cell receptors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination